Halozyme Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,397	1,015	829.25	660.12	443.31
Revenue Growth (YoY)	37.55%	22.44%	25.62%	48.91%	65.66%
Cost of Revenue	228.77	159.42	192.36	139.3	81.41
Gross Profit	1,168	855.91	636.89	520.81	361.9
Selling, General & Admin	207.09	154.34	149.18	143.53	50.32
Depreciation & Amortization Expenses	76.66	71.05	73.77	43.15	-
Research & Development	81.49	79.05	76.36	66.61	35.67
Other Operating Expenses	333.59	-	-	-	-
Total Operating Expenses	698.83	304.43	299.32	253.28	86
Operating Income	469.01	551.48	337.57	267.53	275.9
Interest Income	21.47	23.75	16.32	1.05	1.1
Interest Expense	-18.13	-18.1	-18.76	-16.95	-7.53
Other Non-Operating Income (Expense)	-5.48	-	13.2	-2.71	-20.96
Total Non-Operating Income (Expense)	-2.13	5.66	10.76	-18.61	-27.38
Pretax Income	466.88	557.13	348.33	248.92	248.52
Provision for Income Taxes	149.99	113.04	66.74	46.79	-154.19
Net Income	316.89	444.09	281.59	202.13	402.71
Net Income to Common	316.89	444.09	281.59	202.13	402.71
Net Income Growth	-28.64%	57.71%	39.31%	-49.81%	211.97%
Shares Outstanding (Basic)	120	127	132	137	141
Shares Outstanding (Diluted)	124	129	134	141	147
Shares Change (YoY)	-4.26%	-3.56%	-4.56%	-4.21%	3.77%
EPS (Basic)	2.64	3.50	2.13	1.48	2.86
EPS (Diluted)	2.56	3.43	2.10	1.44	2.74
EPS Growth	-25.36%	63.33%	45.83%	-47.45%	201.10%
Shares Outstanding	117.78	123.14	126.77	135.15	137.5
Free Cash Flow	644.59	468.37	373.28	235.3	297.98
Free Cash Flow Growth	37.62%	25.47%	58.64%	-21.04%	462.76%
Free Cash Flow Per Share	5.20	3.62	2.78	1.67	2.03
Gross Margin	83.62%	84.30%	76.80%	78.90%	81.64%
Operating Margin	33.58%	54.32%	40.71%	40.53%	62.24%
Profit Margin	22.69%	43.74%	33.96%	30.62%	90.84%
FCF Margin	46.15%	46.13%	45.01%	35.65%	67.22%
EBITDA	557.06	632.79	422.43	317.17	278.9
EBITDA Margin	39.89%	62.32%	50.94%	48.05%	62.91%
EBIT	469.01	551.48	337.57	267.53	275.9
EBIT Margin	33.58%	54.32%	40.71%	40.53%	62.24%
Effective Tax Rate	32.13%	20.29%	19.16%	18.80%	-62.04%

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q